Home / Tag Archives: chronic kidney disease (page 2)

Tag Archives: chronic kidney disease

A Newly Discovered Form of Cell Death May Explain Why Diabetes Causes So Many Complications

Scientific illustration showing ferroptosis, an iron-dependent form of cell death, contributing to diabetic complications affecting the kidneys, eyes, nerves, and heart.

Diabetes is known for raising blood sugar levels, but its long-term complications often have the greatest impact on health. Kidney disease, vision loss, nerve damage, and cardiovascular disease affect millions of people living with diabetes. For years, researchers focused on inflammation, oxidative stress, and poor circulation to explain these complications. …

Read More »

Not All Diabetic Kidney Disease Is the Same—Scientists Just Found a Hidden Subtype

Medical illustration showing a human kidney with an enlarged view of immune B-cell activity, representing a newly discovered diabetic kidney disease subtype associated with kidney inflammation.

For years, diabetic kidney disease (DKD) has been viewed as a single condition that progresses in a fairly predictable way. However, new research suggests that this assumption may overlook important biological differences between patients. Scientists have now identified a previously hidden subtype of diabetic kidney disease marked by increased B-cell …

Read More »

Farxiga Just Went Generic—Will Lower Prices Finally Change Diabetes Care?

Prescription bottle of generic dapagliflozin (Farxiga) beside a blood glucose meter, stethoscope, heart model, and kidney model representing diabetes, cardiovascular, and kidney care.

For many people living with type 2 diabetes, the biggest challenge is not finding an effective medication. It is being able to afford it. That reality may begin to change now that the U.S. Food and Drug Administration (FDA) has approved the first generic versions of Farxiga (dapagliflozin), potentially making …

Read More »

When Cardiology Meets Endocrinology: Why Diabetes Care Is Becoming a Team Sport

Multidisciplinary healthcare team including a cardiologist and endocrinologist collaborating on diabetes management with cardiovascular risk assessment in a modern clinical setting.

Not long ago, diabetes management focused primarily on controlling blood glucose levels. Today, that approach has evolved dramatically as cardiologists and endocrinologists increasingly work together to reduce cardiovascular risk. Thanks to groundbreaking cardiovascular outcome trials (CVOTs), clinicians now understand that treating type 2 diabetes means protecting the heart, kidneys, and …

Read More »

Beyond SGLT2 Inhibitors: Why Non-Steroidal MRAs Are Becoming the Third Pillar of Kidney Protection

Illustration of healthy kidneys with medication representing non-steroidal mineralocorticoid receptor antagonists alongside SGLT2 inhibitor therapy for diabetic kidney disease management.

For years, the treatment of diabetic kidney disease focused primarily on glycemic control and blood pressure management. More recently, SGLT2 inhibitors and GLP-1 receptor agonists have transformed the landscape by reducing kidney disease progression and cardiovascular events. However, another therapeutic class is rapidly gaining recognition. Non-steroidal mineralocorticoid receptor antagonists (MRAs) …

Read More »

Getting to 120 Safely: A Practical Guide to Intensive Blood Pressure Management in Diabetes

Healthcare professional monitoring blood pressure in a patient with diabetes using a digital blood pressure monitor, highlighting intensive blood pressure management and cardiovascular risk reduction.

Blood pressure control remains one of the most powerful tools for reducing cardiovascular and kidney complications in people with diabetes. While clinicians have traditionally focused on achieving targets below 140/90 mmHg, recent evidence and the 2026 American Diabetes Association Standards of Care support a more intensive approach for selected high-risk …

Read More »

GLP-1s and CKD Progression: Are Anti-Inflammatory Effects Clinically Meaningful?

Medical illustration of kidneys with GLP-1 therapy pen and molecular model representing GLP-1 CKD progression and anti-inflammatory kidney effects

Chronic kidney disease (CKD) remains one of the most serious complications associated with diabetes, affecting millions of patients worldwide. While SGLT2 inhibitors have become foundational therapies for protecting kidney function, researchers are increasingly examining whether other drug classes may also slow renal decline. In particular, growing interest surrounds how GLP-1 …

Read More »

Reassessing Hypoglycemia Risk in the Era of Modern Therapies

Physician reviewing continuous glucose monitor data with older adult patient showing low blood sugar alert during diabetes consultation

Managing the risk of hypoglycemia remains a central challenge in diabetes care, even as newer therapies lower the rate of severe events. Although GLP-1 receptor agonists and SGLT2 inhibitors have reshaped treatment strategies, insulin and sulfonylureas are still widely used, especially among older adults and patients with chronic kidney disease …

Read More »

SGLT2 Inhibitors in the GLP-1 Era: Why Dual Therapy Matters

SGLT2 inhibitor and GLP-1 agonist medications with heart and kidney illustration representing dual therapy benefits in type 2 diabetes

As GLP-1 receptor agonists dominate headlines and prescribing trends, many clinicians wonder whether older therapies are losing relevance. However, SGLT2 inhibitors remain foundational in type 2 diabetes care. More importantly, evidence now supports the use of SGLT2 inhibitors and GLP-1 combination therapy in patients at high cardiovascular and renal risk. …

Read More »

Inside the ADA 2026 Guidelines: A New Cardiometabolic Roadmap for Diabetes Care

Medical tools including a glucose meter, stethoscope, and ADA 2026 Guidelines clipboard, with digital icons representing cardiometabolic health

The updated ADA 2026 standards represent a major shift in how clinicians approach diabetes management. Rather than focusing solely on lowering A1C, these new recommendations promote a broader, holistic strategy that integrates cardiovascular, kidney, and metabolic (CKM) risk management into everyday care. This article breaks down the key updates and …

Read More »